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 Millions of chronic pain and epilepsy sufferers remain resistant to pharmacotherapy.
 Both disorders are characterised by neuronal hyperexcitability.
 Ion channel gene therapy has emerged as a tool to counteract such hyperexcitability.
 Optogenetics, chemogenetics, and manipulating endogenous channels all show promise.
 We review the key experimental successes and translational challenges of each approach.
Abstract
Chronic pain and epilepsy together affect hundreds of millions of people worldwide. While
traditional pharmacotherapy provides essential relief to the majority of patients, a large proportion
remains resistant, and surgical intervention is only possible for a select few. As both disorders are
characterised by neuronal hyperexcitability, manipulating the expression of the most direct
modulators of excitability – ion channels – represents an attractive common treatment strategy. A
number of viral gene therapy approaches have been explored to achieve this. These range from the
up- or down-regulation of channels that control excitability endogenously, to the delivery of
exogenous channels that permit manipulation of excitability via optical or chemical means. In this
review we highlight the key experimental successes of each approach and discuss the challenges
facing their clinical translation.
1. Introduction
Chronic pain and epilepsy represent major health concerns, together affecting hundreds of
millions of people worldwide at a cost to the global economy of hundreds of billions of dollars [1,2].
In Europe, it is estimated that 0.6-0.7% of the general population suffers from epilepsy [3], and up to
20% will experience chronic pain at some point in their lives [4]. Despite the impressive array of
drugs available to treat these disorders, a significant proportion of patients remains resistant to
traditional pharmacotherapy; 25% of epilepsies are refractory in nature [5], and as many as two-
thirds of chronic pain sufferers are dissatisfied with treatment efficacy [6]. Refractoriness is not the
only concern. Many antiepileptic and analgesic drugs elicit a range of unpleasant side effects that
place restrictive limits on dosing [7,8], and opioid agents used to treat more severe forms of chronic
pain are at high risk of abuse [9]. Because surgical intervention is only possible in a small number of
cases [10,11], there is a pressing need to develop therapeutic alternatives.
One such alternative is gene therapy, which involves the long-term introduction,
overexpression or knockdown of particular genes for therapeutic purposes. In most cases these
manipulations take advantage of the natural infection and genome-editing properties of viruses.
Viral vectors are engineered to encode the therapeutic genes or gene-editing constructs under the
control of promoter elements that target their expression to specific cell types. As such, gene
therapy theoretically provides what traditional pharmacotherapy cannot: a long-lasting intervention
delivered to a pre-determined population of target cells. Though plagued by a number of early
setbacks [12–14], gene therapy now displays considerable promise for the treatment of a number of
neurological disorders [15,16].
Neuronal hyperexcitability is a common feature of epilepsy and chronic pain. In epilepsy,
hyperexcitability emerges from a range of pathological alterations that shift the excitation-inhibition
balance within neuronal networks, leading to the generation of spontaneous, recurrent seizures [17–
19]. These alterations include (among others) the death of GABAergic inhibitory interneurons and
loss of GABAergic synaptic terminals [20,21], the strengthening of excitatory synaptic transmission by
axonal sprouting [22,23], changes in the release and/or re-uptake of excitatory or inhibitory
neurotransmitters [24,25], and changes in the type, number, distribution and activation properties of
particular ion channels or neurotransmitter receptors [26–28]. Neuronal hyperexcitability in chronic
pain can also have multiple underlying causes. These are often grouped according to the type of
chronic pain they produce. “Nociceptive” or “inflammatory” chronic pain arises from persistent
activation and immunoinflammatory sensitisation of primary nociceptive afferents during ongoing
tissue injury [29,30]. In “neuropathic” chronic pain, the culprit is damage to nociceptive neural
pathways; accompanying changes in gene expression can lead to ectopic action potential (AP)
generation that long outlasts the original nerve injury [31,32]. In both types of chronic pain, initial
increases in excitability may be maintained and even amplified by maladaptive strengthening of
transmission across central synapses in the ascending nociceptive pathway, a phenomenon termed
central sensitisation [33,34].
Despite their immensely different aetiologies, because chronic pain and epilepsy are both
characterised by neuronal hyperexcitability, and because the mechanisms underlying excitability are
conserved across a broad range of neurons, any manipulation capable of dampening neuronal firing
might prove therapeutically efficacious in the treatment of both disorders. As the most direct
modulators of cellular excitability, ion channels represent a particularly attractive target in this
regard. Guided by extensive functional data detailing the biophysical characteristics of different ion
channels, a number of viral gene therapy approaches to reducing pathological hyperexcitability have
been explored. These range from the knockdown or overexpression of ion channels that regulate
neuroexcitability endogenously, to the delivery of exogenous channels that permit manipulation of
excitability via optical or chemical means. In this review we discuss the different ion channel gene
therapy approaches that show promise in the treatment of chronic pain and/or epilepsy. We
consider the translational hurdles facing each, as well as the difficulties associated with clinical
progression of gene therapy in general.
2. Optogenetics
The development of optogenetics over the past decade has revolutionised many branches
of basic neuroscience research [35]. The technique employs a set of microbial ion channels and
pumps that activate upon stimulation by particular wavelengths of light. After transgenic expression
within neurons, these type I opsins permit optical modulation of membrane depolarisation or
hyperpolarisation with temporal precision on the order of milliseconds. When combined with the
spatial specificity created by placing opsins under the control of cell type specific promoters, this
generates a system capable of exquisite on-demand regulation of excitability and firing in a
genetically defined population of neurons. In this section we review the therapeutic potential of
optogenetics for the treatment of chronic pain and epilepsy.
2.1. Epilepsy
Epileptiform activity is believed to arise from an excitation-inhibition imbalance within
neuronal networks. This balance can be restored by either downregulating excitation or upregulating
inhibition.
2.1.1. Upregulating inhibition
Upregulation of inhibition can be achieved by optical stimulation of GABAergic inhibitory
interneurons expressing algae-derived channelrhodopsin-2 (ChR2). Activation of this non-selective
cation channel with 450-490nm blue light produces marked neuronal depolarisation and AP firing
[36,37].
ChR2-mediated stimulation of interneurons was recently exploited for therapeutic effect in a
rodent model of temporal lobe epilepsy (TLE). Mice expressing ChR2 exclusively within parvalbumin-
positive (PV+) interneurons were generated by crossing animals expressing Cre under the PV
promoter with those carrying Cre-dependent ChR2. In the resulting PV-ChR2 offspring, in vivo optical
stimulation of the hippocampal formation significantly attenuated established seizures induced by
intrahippocampal injection of kainic acid; almost 60% of seizures detected online via automated
electroencephalographic (EEG) analysis were stopped within 5 seconds of ChR2 activation, and
average seizure duration fell by more than 40% [38]. Although opsin delivery via selective breeding is
obviously not feasible in a clinical setting, this study provided proof-of-principle that optogenetic
stimulation of GABAergic interneurons could attenuate seizures in vivo.
Stimulation of just one genetically defined neuronal population, the perisomatic-targeting
PV+ interneurons, was sufficient to reliably suppress seizures. This result has inevitably fuelled
debate over which interneuronal subtype should be stimulated for optimal anti-seizure efficacy. PV+
interneurons are known to play important roles in subduing and synchronising the axonal output of
CA3 hippocampal pyramidal neurons [39], yet recent recordings from CA1 have suggested dendritic-
targeting somatostatin-positive (SST+) interneurons may have an even stronger influence on
pyramidal cell AP generation [40]. Work from Ledri and colleagues supports an approach based on
global activation of interneurons. In acute hippocampal slices from mice transgenically expressing
ChR2, optical silencing of chemically-induced epileptiform activity was more effective when the
opsin was expressed throughout GABAergic interneurons than when it was expressed specifically
within PV+ or SST+ subpopulations [41].
2.1.2. Downregulating excitation
Downregulation of excitation can be achieved by optical stimulation of excitatory
glutamatergic neurons expressing halobacteria-derived halorhodopsins (HRs). These chloride
pumps are preferentially activated by orange/yellow light with a wavelength ~590nm. When
transgenically expressed within neurons, such activation elicits membrane hyperpolarisation
capable of suppressing the generation of APs [42].
The anti-epileptic potential of HR-mediated neuronal silencing has been investigated by a
number of groups. In early ex vivo work by Tønnesen and colleagues, mouse pups received
intrahippocampal injections of a lentivirus encoding an HR under the control of the glutamatergic
neuron-specific calcium/calmodulin-dependent protein kinase IIα (CaMKIIα) promoter. In 
hippocampal organotypic slice cultures prepared from these animals, optical stimulation significantly
attenuated epileptiform bursting induced by high frequency stimulus trains or the GABAA receptor
(GABAAR) blocker picrotoxin [43].
These promising ex vivo findings set the stage for more recent work demonstrating HR-
mediated seizure suppression in vivo. In a breeding strategy similar to that used to deliver ChR2 to
PV+ interneurons, mice expressing HR exclusively within excitatory principal neurons were
generated by crossing animals expressing Cre under the CaMKIIα promoter with those carrying Cre-
dependent HR. In the CaMKIIα-HR offspring, optical stimulation of the hippocampal formation again 
successfully attenuated established seizures elicited by intrahippocampal kainic acid. Nearly 60% of
seizures detected online were stopped within 1 second of HR activation, and average seizure
duration fell by 70% [38].
As for Cre-dependent delivery of ChR2 to interneurons, the weakness of this approach from
a translational perspective is its reliance on selective breeding to express HR exclusively within
glutamatergic neurons. Should optogenetics progress to the clinic, opsins will need to be delivered
using viral vectors. In work by our group, injection of an HR-encoding lentivirus into layer V of the rat
motor cortex produced preferential expression of the opsin within excitatory principal neurons.
Subsequent optical stimulation of these neurons in a tetanus toxin model of chronic focal
neocortical epilepsy significantly diminished established epileptiform activity in the absence of
behavioural side effects [44].
The relatively selective expression of HR in excitatory neurons was unexpected given that
the transgene was placed under the control of a non-cell type specific cytomegalovirus (CMV)
promoter. For translation to the clinic, a more sensible approach would guarantee glutamatergic
neuron-specific opsin expression with the use of a CaMKIIα promoter. The therapeutic potential of 
such a construct has recently been demonstrated in a rat model of thalamocortical epilepsy [45].
CaMKIIα promoter-driven HR was delivered to excitatory neurons of the ventrobasal thalamus using 
a serotype-5 adeno-associated viral vector (AAV5). Optical stimulation of transduced thalamocortical
neurons reliably interrupted cortical seizures established after photothrombotic induction of stroke.
Intracellular chloride accumulation is a frequent concern in the field of HR-based
optogenetics. Chloride accumulation can shift the reversal potential of GABAAR-mediated inhibitory
postsynaptic currents, causing them to become depolarising [46]. For the treatment of chronic pain
and epilepsy such a shift would be particularly problematic, as optical stimulation would begin to
exacerbate rather than suppress neuronal hyperexcitability. This is especially true for disorders in
which chloride ion homeostasis may already be adversely disrupted, such as TLE [47]. Although not
all HR variants elicit excessive intracellular chloride accumulation [43], the issue can be avoided by
modifying the optogenetic strategy. The use of pulsed rather than continuous optical stimulation, for
example, would allow endogenous chloride extrusion pumps (e.g. KCC2) more time to counteract
chloride influx [48]. Alternatively, HR might be exchanged for a hyperpolarising opsin that pumps
protons rather than chloride ions, such as Arch or ArchT [49,50]. Such proton pumps have yet to be
utilised for in vivo seizure suppression.
2.2. Chronic pain
The transmission of nociceptive signals from the periphery to the spinal cord is mediated by
small-diameter dorsal root ganglion (DRG) neurons. So named for the location of their somata, these
pseudounipolar neurons have a bifurcating axon that projects in one direction to the periphery and
in another to the dorsal horn of the spinal cord. Hyperexcitability within nociceptive afferents is a
critical feature of many forms of inflammatory and neuropathic chronic pain [32,51]. Consequently,
optogenetic silencing of these neurons represents a potentially efficacious alternative to classical
analgesic intervention. Although optogenetic techniques have been used to modulate the firing of
nociceptive neurons in vitro, the feasibility of in vivo therapeutic silencing has long been doubted
due to the misconception that DRG neurons would need to be optically stimulated along their entire
length. As this can be more than a metre in some adult humans, the technical difficulties of total
illumination are self-evident.
However, recent work in rodents suggests these concerns may have been unfounded. Using
an AAV6 vector encoding HR under the neuron-specific synapsin promoter, Iyer and colleagues
expressed the inhibitory opsin within DRG neurons of the mouse hindlimb. Although viral
transduction was not specific for nociceptive neurons, subsequent optical stimulation produced an
acute analgesic effect, and completely reversed the mechanical and thermal hypersensitivity
experienced in a chronic sciatic nerve constriction model of neuropathic pain [52]. An acute
analgesic effect has also been achieved with optogenetic inhibition of DRG neurons expressing the
light-sensitive proton pump ArchT [53]. In an attempt to selectively transduce nociceptive afferents,
an AAV5 vector was designed in which the ArchT transgene was placed under the control of a
transient receptor potential cation channel subfamily V member 1 (TRPV1) promoter; TRPV1 is a
non-selective cation channel preferentially expressed within nociceptive DRG neurons [54]. Optical
stimulation of afferents transduced by direct intraganglion injection of the AAV5 vector resulted in
significant increases in the thresholds for acute thermal and mechanical pain. A very promising
aspect of these two studies was that optical stimuli were delivered transdermally, by shining light on
the hindpaw corresponding to the injected/ligated nerve or ganglion. Techniques such as this, which
eliminate the need for surgical implantation of stimulation devices, will obviously have a
tremendous impact on the speed with which optogenetic therapy can progress to the clinic.
In the work described above analgesic effects were elicited via optogenetic inhibition of
neurons within the ascending nociceptive neural pathway. Endogenously, pain perception is heavily
modified in both a pro- and anti-nociceptive manner by descending projections emanating from
various regions of the brainstem [55–57]. Recent work by Hickey et al. investigated whether
optogenetic stimulation of one such region, the locus coeruleus (LC), could attenuate peripheral
nociception [58]. A lentiviral vector encoding ChR2 under the control of a catecholaminergic-specific
PRS promoter was used to target expression of the opsin transgene to pontospinal noradrenergic
neurons of the LC. In lightly anaesthetised rats, optical stimulation of these neurons in the ventral,
but not dorsal, portion of the LC significantly increased withdrawal thresholds to a thermal
nociceptive stimulus applied to hindpaw. Although this study did not investigate analgesic efficacy in
a model of chronic pain, and experiments were performed on anaesthetised rather than freely
behaving animals, it nevertheless represents an exciting proof-of-concept for modulating pain
perception via optogenetic stimulation of central brain regions. In the future this may prove
therapeutically useful in more global chronic pain conditions that are not amenable to treatment by
local suppression of DRG neuron excitability.
2.3. Translating optogenetics to the clinic
The future for optogenetic therapy of disorders of neuronal hyperexcitability looks bright.
Despite encouraging experimental advances however, several translational hurdles must still be
overcome.
The first of these is a technical issue concerning the miniaturisation of stimulation devices.
The power expenditures required for optical neuromodulation are vast; stimulation of an equivalent
volume of brain tissue by more archaic electrical means can use as little as one-thousandth of the
energy [59]. Creating a fully integrated, implantable device that can generate continuous optical
signals for a therapeutically useful length of time will therefore require considerable battery power,
and as battery power increases, so must device size. These devices need not be implanted at the
site of stimulation; subcutaneous placement will suffice if narrow fibre optic cables are used to
transmit light signals to opsin-expressing neurons. But this does not eliminate the need for
miniaturisation. Indeed the size of implanted equipment is likely to be an important factor
determining acceptance of optogenetic techniques into the clinic, by patients and clinicians alike.
The miniaturisation of optical stimulation devices will be driven predominantly by technical
advances in the fields of bioengineering and power storage [60]. The molecular engineering of
opsins will also contribute. One such innovative approach exploits single amino acid substitutions to
alter opsin deactivation kinetics. The resulting molecules, termed step-function opsins (SFOs),
display prolonged open states that long outlast the activating stimulus [61,62]. From a translational
perspective these SFOs represent an impressive energy-saving tool, capable of dramatically reducing
stimulation device size by permitting long-term (tens of minutes) modulation of neuronal excitability
with short-term (tens of milliseconds) optical illumination.
In the case of epilepsy, an important requirement of optogenetic devices used clinically will
be the ability to simultaneously detect and suppress seizures. Such “closed-loop” systems have
already been trialled in vivo with notable success [38,45,63]. However, their clinical translation will
be hampered by a number of issues. First amongst these is the selection of an appropriate seizure
detection algorithm. Deconstructing EEG traces to reliably and automatically detect epileptiform
activity still represents a central challenge in epilepsy research [64,65], and was recently the subject
of a contest jointly sponsored by NINDS, the American Epilepsy Society and the Epilepsy Foundation
(http://ieeg.org). In a closed-loop system, compromises between the speed and accuracy of seizure
detection will inevitably have to be made, and selecting a suitable approach for the clinic can only
be guided by extensive in vivo testing. One exciting prospect is the emergence of seizure prediction
algorithms for pre-emptive ictal silencing. Although these have classically suffered from poor
reliability, promising recent advances have been made [66].
Unfortunately the creation of closed-loop systems will only exacerbate the issue of device
miniaturisation. Current approaches employ tethered set-ups that connect EEG electrodes to
external amplifiers and computers. Such tethering is obviously not feasible in a clinical setting, and
significant technological advances will be necessary if seizure detection and suppression
capabilities are to be combined into a fully integrated, implantable system.
Perhaps the greatest hurdle facing clinical translation of optogenetics is the poor
penetration of visible light through brain tissue due to photon scattering and absorption [67].
Gradinaru and colleagues, for example, report that light power sufficient to activate an enhanced HR
is only present up to 1.5mm from the tip of an optical fibre with a 30mW output [68]. Although such
shallow penetration might suffice in rodent disease models, producing therapeutic efficacy in
humans with brains many times larger will require optical stimulation of much greater tissue
volumes [48].
Increasing the strength and/or number of optical stimuli seems like the most
straightforward solution to this problem. However, the requisite increases in device size are
undesirable, and local heating effects from sustained stimulation with powers in excess of
100mW/mm2 can lead to irreversible tissue damage [69]. An increase in tissue damage is also likely
to accompany the implantation of multiple optic fibres, particularly if they are targeted to deep
brain regions. Moreover, there is a risk that optical stimulation will be compromised if fibre tips are
encased by connective tissue or shifted out of position after surgery [59]; the probability of such
outcomes evidently increases with an increasing number of fibres.
To overcome the issue of poor light penetration the molecular engineering of opsins may
again prove critical. By rendering opsins more sensitive to optical activation at their preferred
wavelengths, weaker signals further from a stimulating source are able to modulate neuronal
excitability [70]. A more innovative approach increases the sensitivity of opsins to longer
wavelengths of light, creating so-called red-shifted opsins (RSOs) [71,72]. As light of longer
wavelength has greater tissue penetration [73], RSOs also permit modulation of excitability in
neurons much further from an optical source, opening optogenetic stimulation up to deep and
diffuse brain structures for which implantation of optical fibres may be deemed too invasive. In
addition, RSOs also offer the tantalising prospect of non-invasive transcranial optogenetics; as
discussed above, proof-of-principle for transdermal optogenetic modulation of DRG neuron firing
has already been demonstrated [52,53,74]. And finally, RSOs could permit bimodal suppression of
neuronal excitability. Expressing within inhibitory neurons a red-shifted ChR2 with a wavelength
preference matching that of an excitatory neuron-expressed HR would allow coincident excitatory
inhibition and inhibitory excitation by a single-wavelength optical stimulus [69]. It remains to be
seen whether such an approach could be optimised to generate therapeutic efficacy superior to the
single-opsin convention.
The many technical challenges associated with in vivo optogenetic modulation of
neuroexcitability means successful clinical translation is still several years away. However, the
essential role optogenetics now plays in many branches of basic neuroscience research will
continue to drive rapid advances in the technology of stimulation devices [60] and the molecular
engineering of opsins [72,75], both of which will have considerable translational impact.
3. Chemogenetics
The ability to modulate neuronal excitability via on-demand activation of ion channels is
not an exclusive property of optogenetics. Chemogenetic techniques achieve a similar feat using
transgenic expression of channels gated by ligands. As administration of these ligands in vivo is
typically performed systemically, the chemogenetic approach avoids the complications of
optogenetics arising from the need for local light delivery. Invasive surgery apart from injection of
the viral vector is not necessary, and deep and diffuse neural structures can be targeted.
It should be noted that chemogenetic tools are not restricted to ion channels; a number of G
protein-coupled receptors (GPCRs) have been developed that modulate neuronal excitability
indirectly via activation of intracellular second messenger cascades [76–78]. Although these GPCRs
have recently demonstrated impressive anti-seizure efficacy [79], they fall beyond the scope of this
review.
3.1. Chloride channels
Ligand-gated chloride channels permit chemogenetic suppression of neuronal excitability.
The glutamate-gated chloride channel from Caenorhabditis elegans, GluCl, has proven particularly
popular. A heteropentamer composed of α and β subunits, GluCl is activated by ivermectin (IVM), a 
widely used and orally available anti-parasite drug [80]. Since the early demonstration of its ability to
silence neurons [81], GluCl has been optimised for use in mammalian cells [82,83]. One important
modification has been the introduction of a single amino acid substitution that dramatically reduces
the channel’s sensitivity to glutamate [83]. By ensuring GluCl can only be activated by exogenously
delivered IVM, this mutation confers upon the channel the property of orthogonality. Orthogonality,
the lack of endogenous interaction partners for either the receptor or its cognate ligand, is essential
for limiting off-target effects during chemogenetic (and optogenetic) stimulation.
Transgenic expression of GluCl allows regulation of neuronal excitability in vivo in an IVM-
dependent manner. In the first example of behavioural modification using ion channel
chemogenetics, mice received unilateral striatal injections of AAV2 vectors encoding α and β GluCl 
subunits. When IVM was systemically administered via intraperitoneal injection, the resulting
suppression of dopaminergic neurotransmission initiated amphetamine-induced rotational
behaviour. This effect emerged within 4 hours of IVM delivery and was completely reversed 4 days
later [84].
Although behavioural modification using GluCl/IVM has been achieved by numerous groups
since [85–87], the therapeutic potential of the system for treatment of chronic pain and epilepsy has
yet to be evaluated. In addition to its protracted on/off kinetics, the GluCl/IVM system is limited by
the high doses of IVM required to achieve consistent neuronal silencing [88]. As IVM is known to
activate a range of endogenous central nervous system (CNS) receptors at high concentrations [89–
92], this dosing limitation could easily compromise the orthogonality of the system. Such concerns
have recently been assuaged by the design of modified GluCl channels with greater sensitivity to
IVM [93].
One “chemogenetic” chloride channel that has demonstrated therapeutic potential is the
human glycine receptor (hGlyR). Although endogenous expression of hGlyRs within the CNS precludes
any intervention targeted to the brain or spinal cord, the receptor is absent from primary sensory
neurons, suggesting it could be used to suppress DRG neuroexcitability for the treatment of chronic
pain. Employing just such an approach, Goss and colleagues delivered the hGlyR α1 subunit to sensory 
afferents of the rat hindlimb using subcutaneous hindpaw injections of a herpes simplex virus (HSV)
vector [94]. Although viral transduction was not specific for nociceptive DRG neurons, subsequent local
application of glycine generated profound analgesia in two separate models of
inflammatory chronic pain. The system also demonstrated therapeutic efficacy in a model of visceral
inflammatory pain. After injection of the hGlyRα1-encoding HSV vector directly into the bladder 
wall, intravenous glycine administration reversed chemically induced bladder hypercontractility.
3.2. The capsaicin receptor
As demonstrated by the ChR2-based optogenetic strategies described above, chemogenetic
enhancement of excitability within the CNS may prove therapeutically beneficial in the treatment of
chronic pain and epilepsy. For neuronal activation, the best-characterised chemogenetic ion channel
is the TRPV1 receptor. As mentioned above, TRPV1 is a non-selective cation channel expressed
predominantly within nociceptive DRG neurons. An essential nociceptor, the channel is gated by
heat, protons and capsaicin, an active component of chilli peppers that serves as the cognate ligand
in chemogenetic applications [54].
Although the TRPV1/capsaicin system has been used to successfully enhance neuronal
activity both in vitro [95] and in vivo [96], it is unsuitable for clinical use for a number of reasons [88].
First, orthogonality is compromised by endogenous TRPV1 expression within the mammalian brain
[97], and activation of these receptors by endocannabinoid neuromodulators [98]. Second,
transgenic TRPV1 expression has been shown to alter aspects of intrinsic neuronal excitability (e.g.
resting membrane potential) in the absence of capsaicin activation [95]. Third, the calcium
permeability of TRPV1 receptors means high doses of capsaicin can lead to neuronal excitotoxicity
[96]. And fourth, administration of capsaicin to central regions could only be performed by
intracranial infusion, as systemic delivery would activate peripheral TRPV1 receptors causing intense
pain.
Thus, while the TRPV1/capsaicin system may continue to play an important role in
chemogenetic neuronal activation in a research setting [99], the approach does not at present
display therapeutic potential for the treatment of chronic pain or epilepsy.
3.3. Engineered channels and ligands
Engineered ligand-gated ion channels (eLGICs) represent an exciting technical advance in the
field of ion channel chemogenetics. The ligand-binding domain (LBD) of the α7 nicotinic 
acetylcholine receptor (nAChR) behaves as an independent actuator module in the cys-loop family of
ionotropic receptors [100]. This means it can be combined with the ion pore domain (IPD) of any cys-
loop receptor to create a chimeric channel gated by ACh. In recent work by Magnus and colleagues,
α7 LBDs were mutated to yield pharmacologically selective actuator molecules (PSAMs) that are 
unresponsive to ACh but selectively gated by synthetic ligands termed pharmacologically selective
effector molecules (PSEMs) [101]. These PSAM domains were combined with distinct cys-loop
receptor IPDs permeable to calcium ions, cations or chloride ions, creating a toolkit of orthogonal
ligand-gated channels with the ability to depolarise or hyperpolarise neurons in which they were
expressed. Since their creation, these eLGICs have been used by a number of groups in vivo to
chemogenetically modify rodent behaviour [102–105]. As expected given their bespoke design, the
PSAM/PSEM systems display unfailing orthogonality, and relatively rapid on/off kinetics have been
reported (effect onset and brain clearance within one hour of systemic PSEM administration) [101].
Despite such encouraging early results, the therapeutic potential of these engineered
channels for the treatment of chronic pain and epilepsy has yet to be explored. Nevertheless, they
will clearly form the foundation of rapid advances in the development of ion channel chemogenetics
for both basic neuroscience research and clinical intervention. The cys-loop family of ligand-gated
channels comprises no less than 43 vertebrate subunits [106], all with diverse ion selectivity and
conductance properties. This is a vast library from which any IPD could theoretically be selected to
create an orthogonal channel with properties ideally suited to a researcher or patient’s particular
needs.
3.4. Translating chemogenetics to the clinic
While direct evidence for the therapeutic potential of ion channel chemogenetics in the
treatment of chronic pain and epilepsy is still lacking, the approach is clinically attractive. Like
optogenetics, chemogenetics permits on-demand, graded modulation of neuronal excitability in a
genetically defined population of cells. Unlike its optical cousin however, chemogenetics does not
rely on local delivery of an activating stimulus; ligands can be administered systemically (often
orally), allowing deep and diffuse neural structures to be targeted without invasive implantation
of any stimulation device.
One important weakness of the chemogenetic approach is its temporal imprecision [107].
In stark contrast to the millisecond precision of optogenetics, chemogenetic modulation of
neuronal excitability can display onset latencies of tens of minutes to hours depending on the
system used, and there is often a significant delay between the termination of ligand delivery and
the return of excitability to baseline. For the treatment of chronic pain or epilepsy characterised by
persistent seizures, such temporal imprecision could be acceptable, but this is unlikely to be the
case for epileptic conditions in which seizures present sporadically, and patients do not have
sufficient warning to pre-emptively administer an activating ligand. Ictal episodes that are preceded
by premonitory auras or cluster at predictable times (e.g., in catamenial epilepsy) might be more
amenable to chemogenetic intervention [79].
One way that onset latencies might be reduced is through the use of subcutaneous pumps
that deliver activating ligands intravenously. Although these would require surgical implantation,
they would completely abolish temporal delays arising from orogastric absorption of orally
delivered agonists. Pumps could also potentially be incorporated into closed-loop devices that
dispense ligands automatically upon detection of pathological hyperexcitability [79].
4. Overexpression or knockdown of endogenous ion channels
The greatest hurdles facing clinical translation of optogenetic and chemogenetic techniques
stem from their need to deliver exogenous agents, light or ligands, to modulate neuronal
excitability. These hurdles can be avoided by employing a gene therapy strategy that constitutively
modifies the expression of endogenous ion channels. Although the absence of any activating
stimulus removes the capacity to attenuate seizures or pain on-demand, this approach is attractive
for its relative simplicity and the variety of potential targets.
4.1. Modulating intrinsic neuronal excitability
Modulating intrinsic excitability represents the most direct route by which neuronal
firing can be manipulated for therapeutic means. Altering the expression of sodium and
potassium channels allows modification of intrinsic excitability without any effect on calcium-
dependent signalling.
4.1.1. Overexpressing potassium channels
As essential suppressors of intrinsic excitability, potassium channels can be overexpressed
to therapeutically subdue the activity of neurons, or to silence them entirely.
For analgesic purposes, research along this avenue has focussed on the inwardly rectifying
potassium channel 2.1 (Kir2.1). Kir2.1 overexpression has been shown to dampen excitability in
several neuronal subtypes both in vitro [108,109] and in vivo [110]. Adenoviral delivery of the Kir2.1
gene to rat DRG neurons significantly reduced the hyperexcitability emerging from chronic ganglion
compression [111]. When the viral vector was administered immediately after the compression
insult, the development of mechanical hyperalgesia in this model of neuropathic pain was partially
prevented. This finding suggests Kir2.1 overexpression could be used clinically in a preventative
context, to minimise the risk of developing chronic pain after peripheral nerve injury. Delayed
induction of Kir2.1 overexpression did not significantly influence pain behaviour, suggesting the
approach cannot provide analgesic relief after a chronic pain state has already been established.
This lack of effect may be the result of irreversible central sensitisation processes that maintain
upregulated nociceptive signalling irrespective of subsequent changes in primary afferent firing.
For the suppression of neuronal hyperexcitability in epilepsy, two types of potassium
channel have been tested in vivo. In work by our group, established neocortical seizures in a
tetanus toxin rat model of chronic refractory epilepsy were progressively suppressed by lentiviral
delivery of a human voltage-gated potassium channel subfamily A member 1 (KV1.1) gene [44]. A
more recent study has demonstrated the anticonvulsant efficacy of transgenic introduction of a 2-
pore domain potassium leak channel. Intrahippocampal injection of an AAV5 vector encoding a
constitutively active TWIK-related potassium (TREK) channel led to a significant reduction in the
duration of acute seizures elicited by lithium pilocarpine [112]. In both these studies, transgene
expression was observed predominantly within excitatory neurons despite the use of non-cell type
specific promoters. As with any gene therapy approach, it is essential that potassium channels are
overexpressed in the correct neuronal subtypes; high levels of expression within GABAergic
interneurons for example could amplify pathological hyperexcitability.
4.1.2. Knocking down voltage-gated sodium channels
Voltage-gated sodium channels (Navs) are important enhancers of intrinsic excitability,
making Nav knockdown an attractive approach in the therapeutic attenuation of neuronal
activity.
Chronic pain seems particularly amenable to gene therapy approaches based on Nav
knockdown; Nav upregulation contributes heavily to the increases in DRG neuron excitability seen
in neuropathic [113,114] and inflammatory [115,116] pain disorders, and many clinically prescribed
analgesic drugs function by Nav antagonism [117].
To avoid unwanted side effects arising from global Nav knockdown within somatosensory
afferents, therapeutic strategies have focussed on Nav isoforms expressed predominantly within
nociceptive neurons. Nav1.7, encoded by SCN9A, is one such isoform. Abundantly and
preferentially expressed within nociceptive DRG neurons [118], Nav1.7 mutations are associated
with a range of genetic pain disorders [119,120]. In 2005 Yeomans and colleagues investigated the
therapeutic potential of DRG Nav1.7 knockdown for the treatment of inflammatory chronic pain
[121]. Transgenic expression of an HSV vector-delivered SCN9A antisense sequence completely
prevented the emergence of thermal hyperalgesia after hindpaw injection of the
immunopotentiator complete Freund’s adjuvant (CFA). Nav1.7 knockdown in DRG neurons has also
proven therapeutically efficacious in a rat model of painful diabetic neuropathy (PDN). HSV vector
delivery of a Nav-targeting microRNA completely reversed the increases in DRG Nav1.7 expression
that followed induction of diabetes with streptozotocin, and in doing so significantly reduced PDN-
associated cold allodynia and thermal and mechanical hyperalgesia [122].
Nav1.7 is not the only isoform whose knockdown may provide long-lasting protection from
chronic pain; Nav1.3, encoded by SCN3A, is another promising candidate. Although normally
expressed at very low levels in adult neurons [123], Nav1.3 expression is dramatically upregulated
following nerve injury [124], when the isoform is thought to play an important role in the
emergence of neuronal hyperexcitability [125]. In recent work from the group of Stephen Waxman,
two Nav1.3-targeted short hairpin RNAs (shRNAs) were packaged into separate AAV2 vectors
injected directly into the DRG of rats with partial ligation of the sciatic nerve. The resulting Nav1.3
knockdown led to partial attenuation of mechanical allodynia in this model of neuropathic pain;
both shRNAs were equally efficacious [126].
These studies demonstrate the therapeutic potential of isoform-specific DRG Nav
knockdown for the treatment of inflammatory and neuropathic chronic pain. Although sodium
channels are strongly implicated in epileptogenesis, and several front line anti-epileptic drugs
selectively inhibit these channels [127,128], Nav knockdown has yet to be investigated for its
therapeutic effect in models of epilepsy. This may be due to difficulties in selecting an appropriate
Nav target, or concerns about potential off-target effects on physiological network activity.
4.2. Modulating synaptic excitability
Modulating intrinsic excitability is not the only way by which neuronal firing can be manipulated.
Within neuronal networks, activity can also be modified by varying the degree of excitatory or
inhibitory synaptic input. One way to achieve this is via up- or down-regulating the expression of
excitatory or inhibitory neurotransmitter receptors. From a gene therapy perspective, the most
popular targets in this regard have been NMDA and GABAA receptors.
4.2.1. Knocking down NMDA receptors
NMDA receptors (NMDARs) play a critical role in excitatory glutamatergic synaptic
transmission within the CNS. Receptor activation results in a non-selective cation flux that underlies
the slow component of the fast excitatory post-synaptic current [129]. Increases in post-synaptic
calcium following NMDAR activation are known to be crucial for activity-dependent strengthening
of synaptic transmission [130], and this synaptic plasticity is often essential for long-term
enhancement of network excitability. Perhaps unsurprisingly therefore, a number of studies have
explored the therapeutic potential of NMDAR knockdown for the treatment of disorders of
neuronal hyperexcitability.
Early work by During and colleagues took an unusual approach, investigating whether
functional NMDAR knockdown could be achieved by eliciting a humoral immune response against
the receptor’s obligatory NR1 subunit [131]. Transduction of intestinal M cells using a perorally
administered NR1-encoding AAV was used to generate this response. Surprisingly, the resulting
anti-NR1 antibodies seemed to protect sensitised animals against seizures induced by systemic
kainic acid. Moreover, the relative impermeability of the non-seizure-compromised blood-brain
barrier (BBB) to the antibodies ensured NMDAR blockade was minimal under resting physiological
conditions. Despite these encouraging experimental outcomes, this approach is probably unfeasible
from a translational perspective. The risk of side effects arising from global NR1 knockdown is
significant, and anti-NR1 antibodies are now thought to be pathogenic in their own right [132].
The therapeutic potential of NMDAR knockdown using more direct gene-silencing constructs
has also been investigated. AAV-mediated delivery of a CMV-driven NR1 antisense sequence was shown
to significantly increase thresholds for the electrical induction of focal seizures in the rat temporal cortex
[133]. Similar anticonvulsant efficacy has been achieved with shRNA-mediated NR1 knockdown.
Intrahippocampal injection of an AAV1/2 chimera encoding an NR1-targeted shRNA under the control of
the non-cell type specific U6 promoter protected rats against seizures induced by local kainic acid
administration [134]. However, such protection came at the expense of impaired hippocampal-
dependent learning and compromised neurogenesis. Whether these adverse effects will render central
NMDAR knockdown clinically untenable remains to be seen.
NMDAR knockdown outside the brain may display a more forgiving side effect profile, and
several studies have investigated this approach for its analgesic potential [135–138]. The first
synapse in the ascending nociceptive neural pathway, between DRG primary afferents and
neurons of the spinal cord dorsal horn, has proven a particularly popular target; NMDAR-
dependent strengthening at this synapse can underlie certain forms of central sensitisation [139].
In work by Garraway and colleagues, an AAV vector encoding an NR1-targeted shRNA was
delivered directly to the dorsal horn of mice by intraparenchymal injection. The resulting NR1
knockdown had no effect on the perception of acute nociceptive stimuli, but did prevent the
emergence of mechanical allodynia after CFA-mediated induction of inflammatory chronic pain
[140]. Similar findings were obtained in rats with chronic pain induced by the inflammatory agent
formalin [141]. These studies suggest that inhibiting central sensitisation by knocking down
NMDARs at the DRG neuron-dorsal horn synapse may prove therapeutically efficacious in
preventing the emergence of chronic pain after peripheral tissue damage.
4.2.2. Overexpressing GABAA receptors
GABAARs play an essential role in inhibitory synaptic transmission within the CNS.
Overexpressing this chloride-permeable ionotropic receptor thus has the potential to therapeutically
suppress local network excitability. Within the dentate gyri of pilocarpine rat models of TLE, there are
significant reductions in the expression of GABAAR α1 subunits accompanied by significant increases in 
levels of α4 [142,143]. In an innovative attempt to reverse this α1 deficit, Raol and colleagues designed 
an AAV2 vector that encoded the α1 gene (GABRA1) under the control of the α4 gene (GABRA4)
promoter. When this vector was injected directly into epileptic dentate gyri, the enhanced α1 
expression not only attenuated acute pilocarpine-induced seizures, but also decreased by 60% the
number of rats that went on to develop established epilepsy [144]. It should be noted that a
significant proportion of AAV2-α1-treated rats experienced behavioural abnormalities such as 
excessive sedation and weight loss. This suggests that, as with NMDAR knockdown, the clinical
translation of GABAAR overexpression may be hindered by adverse side effects.
4.2.3. Knocking down TRPV1 receptors
Although the knockdown of TRPV1 receptors within DRG neurons strictly represents a
modification of neither intrinsic nor synaptic excitability, the approach has recently been used for
mild analgesic effect in a mouse model of neuropathic pain [145]. A TRPV1-targeting shRNA was
packaged into an AAV9 vector and administered via intrathecal injection to mice with partial
ligation of the sciatic nerve. TRPV1 knockdown resulted in a slight but significant increase in the
hindpaw withdrawal threshold to a 50°C thermal stimulus. However, the fact that no significant
changes were observed in withdrawal thresholds for a thermal stimulus 5°C hotter, an acetone-
induced noxious cold stimulus, or a focal mechanical stimulus suggests this approach may struggle
in its clinical translation.
4.3. Translating overexpression or knockdown of endogenous ion channels to the clinic
Gene therapy approaches based on overexpression or knockdown of endogenous ion
channels will likely progress to the clinic much more rapidly than optogenetic or chemogenetic
methods. Technical hurdles stemming from the need to deliver activating light or chemical stimuli
do not exist, and the burden of pre-clinical safety and tolerability testing will probably be
significantly lighter for human genes than those derived from distant species [146].
Nevertheless these approaches still face a number of translational hurdles. Of particular
concern is the constitutive nature of the therapy, which could prove problematic for several
reasons. First, constitutive manipulation of neuronal excitability is more likely to be counteracted by
homeostatic compensatory mechanisms than a therapeutic intervention delivered transiently and
intermittently [147]. Such compensation could adversely influence excitability in other parts of the
network, or simply abolish the beneficial effects of transgene expression, generating the need for
repeat vector administrations that become progressively less efficacious. The latter concern might
be assuaged by the delivery of transgenes specifically designed to resist compensatory
downregulation [112].
Second, constitutive manipulations will suppress neuronal excitability continuously, whether
pathological activity is present or not. The aim of these interventions is to abolish disease-related
hyperexcitability, but the silencing of physiologically salient neuronal communication could generate
unwanted treatment side effects. This is less of a concern for chronic pain or epilepsies characterised by
persistent seizures, such as epilepsia partialis continua, where ongoing suppression of excitability is
therapeutically necessary [148]. In the vast majority of epileptic conditions however this is not the case,
and seizures present sporadically separated by long periods of interictal activity. Unfortunately the
effects of ion channel gene therapy on interictal activity are often ignored, and appropriately titrating a
given treatment to minimise the silencing of normal neuronal function can be challenging.
Finally, should constitutive modulation of neuronal excitability produce unwanted side
effects, the intervention cannot simply be “switched off”, as is achieved in optogenetics and
chemogenetics by removal of the activating stimulus. Such irreversibility in the face of adverse
treatment outcomes will necessitate careful subject selection in the early phases of human
testing. For epilepsy, patients with seizure foci deemed suitable for surgical resection would be
ideal, as transduced tissue could be immediately excised if undesirable side effects were to arise
[44,146].
5. General considerations for the creation and translation of efficacious
gene therapy
The studies presented above highlight the great variety of transgenes used to
manipulate ion channel expression in the therapeutic attenuation of neuronal
hyperexcitability (summarised in Figure and Table). Selecting an appropriate transgene
though is only the first step in producing a clinically viable gene therapy. To ensure expression
is achieved in the desired target neurons at levels sufficient to counteract pathological firing,
all in the absence of adverse side effects, the promoter and viral vector employed for
transgene delivery must be carefully considered. In this section we review the different
promoters and vectors that have been used in studies of gene therapy for chronic pain and
epilepsy. We then discuss the regulatory, manufacturing and socioeconomic hurdles facing
clinical translation of gene therapy in general. A comprehensive discussion of vector design,
testing and approval is beyond the scope of this article; more detailed accounts can be found
in several excellent recent reviews [15,146,149–152].
5.1. Viral vectors
Viral vectors vary considerably in their suitability for different therapeutic applications. In
studies investigating ion channel gene therapy for chronic pain and epilepsy, four have so far
been used: lentiviral, AAV, HSV and, to a lesser extent, adenoviral vectors.
5.1.1. Adenoviral vectors
Adenoviral vectors have proven a popular delivery strategy in several gene therapy applications,
particularly those targeting cancer and liver disease. The vectors have a transgene packaging capacity of
~8kb (can be increased to >35kb in so-called “gutless” vectors), and can efficiently transduce post-
mitotic neurons to support high levels of transgene expression. Despite this, adenoviruses are rarely
selected for transgene delivery in the treatment of neurological disorders [149]; indeed just one of the
studies presented above employs an adenoviral vector [111].
The most likely reasons for this are the vectors’ tendency to support only short-term
transgene expression and their significant immunogenic potential. The seriousness of this
immunogenicity was made clear in an early clinical trial of enzyme replacement therapy for the
non-fatal disease ornithine transcarbamylase (OTC) deficiency. 18-year-old Jesse Gelsinger suffered
an acute immunoinflammatory response after intravenous delivery of an OTC-encoding adenoviral
vector, and died from multiple organ failure 4 days later [12]. Although adenoviral vectors can be
engineered to reduce their immunogenic potential [153], and the risks of an acute systemic
response are greatly diminished by delivery directly into the immune-privileged CNS, this early trial
continues to bias vector selection for neurological gene therapy against adenoviruses.
5.1.2. AAV vectors
AAVs are the most common vector in clinical trials of gene therapy for neurological disease
[149]. Their popularity is reflected in the large number of studies that have employed AAV-mediated
transgene delivery in preclinical testing of gene therapy for chronic pain and epilepsy
[45,52,53,112,126,131,133,134,140,141,144,145]. Like adenoviral vectors AAVs are capable of
transducing post-mitotic neurons, but can support transgene expression of much longer duration
(up to 8 years in non-human primates (NHPs) [154]). Moreover, AAVs are not associated with any
human diseases and although they can elicit both humoural and cell-mediated immune responses,
these tend to result simply in vector elimination rather than acute systemic reactions [155].
AAV vectors do have limitations however. First amongst these is their relatively small
transgene packaging capacity (~4.5kb), which may preclude delivery of therapeutic constructs
containing large promoter elements and/or ion channel genes. Another disadvantage is their
occasional propensity for genomic integration. Although the vast majority (~99%) of AAV-delivered
DNA persists in extrachromosomal episomes, a small proportion of vectors integrate their DNA into
the genome of the host cell [156,157]. Such integration is concerning as it can lead to a
phenomenon known as insertional mutagenesis, where potentially catastrophic mutations arise
from genomic insertions within or near the coding regions of actively transcribed genes. While the
large proportion of non-coding DNA in the human genome makes insertional mutagenesis unlikely,
the consequences of ignoring the possibility can be disastrous. In a 2002 gene therapy trial,
retroviral delivery of a γc chain transgene to patient-derived CD34+ bone marrow cells was initially 
successful in treating X-linked severe combined immunodeficiency (X-SCID) [158]. A subset of
patients soon developed a leukaemia-like condition however, the cause of which was traced to
transcriptional disruption arising from transgenic integration near the LMO-2 proto-oncogene [13]. No
such adverse outcomes have arisen from human gene therapy trials employing AAV vectors, but
oncogenic insertional mutagenesis after AAV-mediated transgene delivery has been observed in rodents
[159].
AAVs comprise 12 identified human and NHP serotypes, and over 100 isolated variants with
unestablished serology [160]. Such variety, which stems from structural differences in the protein
shell (capsid) of the virus, has provided a range of vectors with diverse properties suiting different
gene therapy applications. One property that varies considerably among AAV serotypes is viral
tropism – the specific cells or tissues a virus will preferentially, or exclusively, transduce. In the CNS
for example, AAV8 and AAV9 serotypes only infect neurons [161], while AAV5 vectors have been
reported to transduce both neurons and astrocytes [162]. Selection of an appropriate serotype can
therefore play an important role in determining the cell type specificity of transgene expression.
Viral pseudotyping, in which one viral genome is packaged into the wild-type or modified capsid of
a second with preferable tropism, has proven valuable in the design of recombinant vectors with
transduction properties specifically suited to a researcher’s particular needs [160,163].
Serotype variety has also kept AAV vectors at the forefront of strategies aimed at solving
the so-called “volume obstacle” of gene therapy translation [48]. Briefly alluded to above, this term
refers to the increases in viral transduction volume that may be necessary if therapeutically
efficacious vector delivery in rodents is to be successfully translated to humans with brains many
times larger. Increasing the spread of viral transduction through CNS tissue will be especially
important for treating more global neurological pathologies, including generalised epilepsies where
small, spatially restricted foci of hyperexcitability do not exist.
A number of different delivery strategies have exploited AAV serotype variety to achieve
such increases in viral transduction volume [15]. These include the use of serotypes that spread
further from the site of single stereotaxic injections (e.g. AAV9 and AAV10) [164]; the delivery of
serotypes amenable to transport along neuronal pathways (e.g. AAV8 and AAV9) into brain
nuclei with divergent connectivity [165,166]; and vector injection directly into cerebrospinal fluid
spaces (e.g. AAV4 and AAV5) [162]. Another innovative approach involves intravenous
administration of serotypes that are BBB-permeable, such as AAV9 [167]. With respect to
epilepsy, a very exciting advance has been the combination of multiple capsid serotypes into
chimeric AAV vectors that selectively cross the seizure-compromised BBB [168].
5.1.3. Lentiviral vectors
Lentiviral vectors are also able to support long-lasting transgene expression within post-mitotic
neurons when appropriately pseudotyped. They are currently the second most popular vector for CNS
gene therapy [149], and have been employed by a number of studies investigating such treatments for
epilepsy and pain [43,44,58]. Relative to AAV vectors their advantages include a larger transgene
capacity (~9kb) and a virtually non-existent immunogenic profile [169].
As with all members of the retrovirus family, lentiviruses naturally integrate their DNA into
the host cell’s genome, meaning the risk of insertional mutagenesis with these vectors is relatively
high. This risk is amplified by the fact that several lentiviral subtypes, such as HIV-1, display an
integration location bias for transcriptionally active genes [170]. Fortunately safety concerns
regarding genomic insertion have been largely mitigated by the design of therapeutically
efficacious integration-deficient lentiviral vectors [171].
5.1.4. HSV vectors
HSV vectors are non-integrating, highly infectious viruses that preferentially transduce
neurons. They display a vast transgene capacity (>100kb), meaning almost any therapeutic
construct, or combination of constructs, can be delivered in a single vector. Despite these
advantageous features, very few clinical trials for CNS gene therapy have employed HSV vector
delivery strategies [149], perhaps because of their frequent inability to support long-term
transgene expression (but see ‘Promoters’ section below).
One application for which HSV vectors have proven very popular is transgene delivery to DRG
neurons [94,121,122]. The unique infection cycle of wild-type HSV explains why. HSV released from
infected skin or mucosal membranes invades the peripheral nerve endings of DRG neurons, where the
virus is retrogradely transported along the entire length of the peripheral axon branch to the soma
[172]. From a gene therapy perspective this retrograde transport is ideal, as it abolishes the need
to deliver vectors by direct injection into relatively inaccessible ganglia. Instead, vectors can be
administered peripherally via intradermal inoculation, ensuring only those afferents innervating
the painful dermatome(s) are transduced.
The retrograde transport of HSV vectors could be utilised centrally to increase the spread
of viral transduction through brain tissue [173,174]. Such increases might contribute to a solution
for the aforementioned “volume obstacle” of gene therapy translation.
5.2. Promoters
An important decision in the design of gene therapies for epilepsy and chronic pain is
whether to suppress pathological hyperexcitability directly by quelling the activity of excitatory
principal neurons, or indirectly by boosting the firing of inhibitory interneurons. Whichever
approach is chosen, it is vital that the transgene be expressed exclusively within the correct target
neurons; accidental suppression of firing within inhibitory interneurons for example would
exacerbate rather than attenuate network hyperexcitability. Although the choice of vector can
determine cell type specificity up to a point (e.g. in the distinction between glia and neurons),
reliably expressing a transgene within a predetermined neuronal subtype almost always requires
the use of cell type specific promoter elements. For excitatory glutamatergic neurons the element
of choice is the CaMKII promoter, while for inhibitory GABAergic neurons glutamate decarboxylase
(isoform 65 or 67) promoters are the most popular. Subpopulations of GABAergic interneuron may
also be selectively targeted using, for example, PV or SST promoters.
The importance of driving transgene expression using cell type specific promoters was
demonstrated in early work by Haberman and colleagues [133]. To suppress seizure-inducing
hyperexcitability via NMDAR knockdown, they used two independent non-cell type specific
promoters to drive expression of an NR1 antisense sequence within neurons of the rat temporal
cortex. When transgene expression was driven using a CMV promoter, there was an increase in the
threshold for induction of focal seizures by electrical stimulation. When the transgene was placed
under the control of a promoter suppressed by the presence of tetracycline (the Tet-off promoter)
however, seizure induction thresholds were significantly reduced. Immunohistochemical analysis
demonstrated that these opposite effects likely arose from NR1 antisense expression within
distinct neuronal populations: excitatory principal neurons with the CMV promoter and inhibitory
interneurons with the Tet-off construct.
This result highlights the inherent unpredictability of driving transgene expression with strong
non-cell type specific promoters. But because many commercial viral vectors are supplied with such
elements, this strategy is often employed [44,133,134]. Even if cell type specific expression can be
achieved with a non-selective promoter in rodent models however, it should not be assumed such
specificity will be replicated in humans. As a case in point, lentiviral delivery of a CMV-driven transgene
to the rat motor cortex leads to preferential expression within excitatory principal neurons [44], yet a
similar vector-promoter combination delivered to the motor or visual cortices of NHPs elicits transgenic
expression almost exclusively within glial cells [164]. This difference highlights the importance of
thoroughly characterising the cell type specificity of transgene expression in multiple animal models
before a therapeutic vector progresses to clinical trials.
Promoters also play an important role in determining the longevity of transgene expression.
For most gene therapy applications long-term, even indefinite, expression is preferable. The
advantages of such longevity are clear; the viral vector need only be delivered once, increasing
patient compliance and reducing the risk of eliciting an immune response against repeat
administrations. In reality though long-term transgene expression is often difficult to achieve. One
reason for this is promoter silencing. Although this phenomenon can occur with a number of
therapeutic vectors, those based on HSV are particularly susceptible [175]. Even strong
constitutively active promoters such as CMV are silenced within a few weeks of neuronal
transduction [176–178]. HSV latency-active promoter 2 (LAP2) sequences may offer a solution to
the problem. In wild-type HSV, the LAP2 element escapes silencing while the virus lies dormant in
infected neurons [179]. Vectors containing LAP2 promoters have been shown to support CNS
transgene expression lasting several months [180,181], and it is thought they might be combined
with cell type specific promoters to achieve similar longevity in genetically identified neuronal
populations [150].
Despite the general preference for constitutive transgene expression, the ability to
terminate transcription in the event of adverse side effects would be extremely attractive from a
clinical perspective. Such termination can be achieved with inducible promoters. In these
systems, exogenous pharmacological agents are delivered to either activate or suppress
promoter-driven transcription [182]. Although inducible promoters have been incorporated into
vectors for gene therapy of chronic pain and epilepsy [111,133], their progression to the clinic
will be restricted by the need for additional toxicology and tolerability testing of pharmacological
components.
5.3. Regulatory, manufacturing and socioeconomic translational hurdles
1990 saw the first human clinical trial for gene therapy [183]. 22 years and hundreds of
trials later, alipogene tiparvovec (AAV1-LPLS447X; Glybera) became the first such treatment to
achieve regulatory approval in the Western world [184,185]. This extremely low conversion rate
reflects the difficulties faced in translating experimentally promising gene therapies to the clinic. In
this section we review these difficulties and offer tentative suggestions for how they might be more
successfully overcome.
Perhaps the greatest challenge to gene therapy translation comes from regulatory agencies.
In Europe and the USA, gene therapy is subject to the same regulatory controls as traditional
pharmacotherapy [186]. As such, viral vector production must comply with good manufacturing
practice (GMP) guidelines, and therapeutic efficacy must be determined in multi-phase human
clinical trials. The academic research facilities in which most gene therapy vectors are designed
rarely have the infrastructure, financial resources or expertise necessary to meet these demands.
There therefore exists a strong argument for the creation of publically subsidised or privately
funded consortia that might shoulder the responsibility [187].
Whether these calls for greater financial collaboration are heard or not, regulations could
certainly be relaxed to allow consenting patients faster access to promising but as-yet-unapproved
gene therapies. Although extensive analyses of efficacy, toxicology and tolerability have their
benefits, for many patients suffering from diseases refractory to traditional treatments gene
therapy represents a last resort, and regulatory restrictions should take this into account if
individuals are willing to accept the inherent risks of an incompletely tested therapeutic agent
[186]. With respect to toxicology and tolerability, academics responsible for vector design could
speed up translation by employing vector backbones that have already been characterised [188].
It is reasonable to assume that the clinical translation of gene therapy might benefit from
greater pharmaceutical involvement in vector production and testing. Thus far contribution from
these companies has been minimal, possibly due to concerns regarding the small financial returns
on offer. Viral vector production would necessitate infrastructural updates to manufacturing and
storage facilities, and the cost of these would be difficult to recoup from sales of biotherapies
designed to be administered just once to (initially) small populations of patients. Moreover,
pharmaceutical companies are unlikely to willingly sacrifice profit by introducing market
competition for their highest-earning pharmacological agents.
An additional concern for gene therapy translation is public opinion of the approach.
Adverse outcomes from early clinical trials [12,13] continue to cast a shadow in the minds of
patients and clinicians alike. From the clinician’s perspective, the perceived complexity of genetic
approaches relative to established pharmacotherapy may initially limit clinical usage. This
complexity issue will be particularly relevant for combination therapies such as chemogenetics and
optogenetics [59].
Despite the many translational hurdles gene therapy faces, the technique has recovered
from early setbacks to demonstrate genuine promise for the treatment of a wide variety of
disorders. The growing list of successful human trials [16] will continue to assuage regulatory,
financial and social concerns surrounding the approach, generating momentum for the translation
of many more therapeutic vectors.
6. Conclusions and perspectives
Chronic pain and epilepsy are ideally suited to therapeutic interventions targeted at
suppressing neuronal hyperexcitability. The manipulation of ion channel expression using viral gene
therapy represents one such intervention that is already progressing from proof-of-principle
research to the clinic.
From a translational perspective the most straightforward ion channel targets are those
that regulate excitability endogenously. While optogenetic and chemogenetic approaches display
promise in an experimental setting, the added complexity of activation by exogenous stimuli will
inevitably slow their clinical development. Conversely, for the genetic manipulation of endogenous
protein expression there have already been numerous successful clinical trials for various disorders
and one approved treatment. To identify similar gene therapy strategies capable of treating chronic
pain and epilepsy, further preclinical testing will be necessary to guide rational selection of
appropriate transgenes. So far these have consisted primarily of ion channel cDNAs or shRNAs
targeting ion channel genes. However, exciting recent advances in gene-editing technologies such as
the CRISPR-Cas9 system could soon open the door to an entirely novel set of transgenic tools
capable of not only upregulating or downregulating ion channel expression, but also repairing
disease-causing channel mutations.
To speed up clinical translation, therapeutic transgenes should be packaged into vectors
already characterised for toxicology and tolerability within human patients. As the gold standard for
delivery of exogenous genetic material, viral vectors have formed the central focus of this review. It
will be interesting to see whether emerging technologies such as nanoparticles can overcome the
established bias against non-viral delivery strategies. Whatever strategy is used, the performance of
therapeutic vectors within clinical trials for chronic pain and epilepsy will depend heavily on the
degree to which regulatory, financial and social concerns surrounding gene therapy are addressed,
and ideally, relaxed.
Figure: Schematic of the different gene therapy approaches used to alter neuronal excitability via
the manipulation of ion channel expression. The activity of a hypothetical neuron is represented
on the right as vertical spikes along a baseline. Optogenetic channels permit light-mediated
enhancement (ChR2) or suppression (HR, ArchT) of neuronal firing with a stimulus duration on the
order of millisecond/seconds. Chemogenetic channels also permit bidirectional modulation of
spiking. Neuronal firing is dampened by chloride ion influx through GluCl, hGlyR, and eLGICs-
channels, and increased by cation flow through TRPV1 and eLGICs+ channels. In both cases the
channels are activated by pharmacological stimuli with effect durations on the order of minutes to
days. The expression of endogenous ion channels can be manipulated to suppress neuronal
excitability by increasing potassium ion efflux (Kir2.1, Kv1.1, TREK), reducing cation influx (Nav,
NMDAR, TRPV1), or increasing chloride influx (GABAAR). In all cases the effects are long lasting and
most will likely be considered permanent in a clinical setting. As indicated by the small number of






Potential Analgesic Potential Key References
Feasible? Tested? Feasible? Tested?
Optogenetic
Channels
ChR2 Λ Y Y Y Y
Krook-Magnuson et al. (2013) [38]
Ledri et al. (2014) [41]
Hickey et al. (2014) [58]
HR V Y Y Y Y
Tønnesen et al. (2009) [43]
Krook-Magnuson et al. (2013) [38]
Wykes et al. (2012) [44]
Paz et al. (2013) [45]
Iyer et al. (2014) [52]
ArchT V Y N Y Y Li et al. (2015) [53]
Chemogenetic
Channels
GluCl V Y N Y N n/a
hGlyR V N N Y Y Goss et al. (2011) [94]
eLGICs- V Y N Y N n/a
TRPV1 Λ N N N N n/a
eLGICs+ Λ Y N Y N n/a
Endogenous
Channels
Kir2.1 (↑) V Y N Y Y Ma et al. (2010) [111]
Kv1.1 (↑) V Y Y Y N Wykes et al. (2012) [44]
TREK (↑) V Y Y Y N Dey et al. (2014) [112]
Nav (↓) V Y N Y Y
Yeomans et al. (2005) [121]
Chattopadhyay et al. (2012) [122]
Samad et al. (2013) [126]
NMDAR (↓) V Y* Y Y Y
During et al. (2000) [131]
Haberman et al. (2002) [133]
Kalev-Zylinska et al. (2009) [134]
Garraway et al. (2007) [140]
Garraway et al. (2009) [141]
GABAAR (↑) V Y* Y Y N Raol et al. (2006) [144]
TRPV1 (↓) V N N Y Y Hirai et al. (2014) [145]
Table: Summary of the different ion channels investigated for gene therapy of chronic pain and
epilepsy. For endogenous channels, arrows refer to the direction of the manipulation (↑ or ↓ for 
up- or down-regulation of expression, respectively). Λ and V represent the predicted effect of a 
given manipulation on neuronal firing (enhancement or suppression, respectively). Y (yes) and N
(no) denote whether a given channel has been (Tested?) or could be (Feasible?) effectively utilised
in gene therapy for epilepsy and/or pain. Theoretically promising manipulations that have not yet
been tested are highlighted in grey. *denotes adverse side effects that may limit the therapeutic
potential of central NMDAR knockdown or GABAAR overexpression.
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